industry project

Antibacterial Drugs Market Detailed Analysis and Forecast by 2023

Press Release   •   Nov 01, 2016 02:23 EDT

An antibacterial drug is referred to as an antimicrobial agent interfering with the growth and reproduction of bacteria that cause numerous mild to severe infections in humans and animals. Antibacterial drugs either kill or inhibit their growth. These agents possess bactericidal activity which target various parts of bacterial physiology such as protein synthesis, cell wall synthesis, nucleic acid synthesis and permeability of cell membrane, and therefore help in treating infections. Antibacterial drugs are being in use since the discovery of the first antibacterial in the form of penicillin in 1928, and presently a wide range of antibacterials in several formulations are commercially available and used for the treatment of various indications like pneumonia, tuberculosis, tetanus, diphtheria, diarrhea, legionellosis and other diseases.

Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1040

The global antibacterial drugs market has been categorized into eight segments based on their class which include: aminoglycosides, β-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides, phenicols, and miscellaneous antibacterials. In 2014, β-lactams occupied the leading position with a share of 57.7% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness a decline in their market share during the forecast period due to scheduled patent expiry of key branded formulations, coupled with growing number of drug resistant bacterial strains and increasing influx of generic drugs. Hence, on account of the factors mentioned above, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2015 to 2023. However, the miscellaneous antibacterials segment is expected to grow with the highest CAGR accompanied with growing demand for therapies against bacterial infections and rising geriatric populations are some of the factors that are anticipated to maintain the growth of the antibacterial drugs market. Additionally, expected commercialization of various antibacterial agents that are currently in developmental stages, such as solithromycin (Cempra, Inc.), VivaGel (SPL7013) (Starpharma Holdings Limited), surotomycin (Merck & Co.) MK-3415A (Merck & Co.) during the forecast period is also expected to profound impact on growth of this market.

Inquiry on this report @ http://www.mrrse.com/enquiry/1040

Asia-Pacific held the largest share of the revenue generated by the global antibacterial drugs market in 2014. This region is also expected to experience the highest growth rate during the forecast period 2015 to 2023. The major factors responsible for this region to hold leadership in this market in 2014 include presence of large number of generic manufacturers and active pharmaceutical ingredient (API) manufacturers in Asian countries, growing incidences of bacterial infections such as MRSA (methicillin resistant Staphylococcus aureus) and tuberculosis and increasing purchasing power of the domestic population. Moreover, developing health care infrastructure, presence of a large population base and growing geriatric population which is more prone to diseases would consequently increase the uptake of antibacterial drugs in Asia. North America held the second largest revenue share followed by Europe in the antibacterial drugs market in 2014. Market maturity, shortened product lifecycle, stringent regulatory requirements and generic infiltration are some of the factors that accounted for slow growth of this market.

Read Complete Report @ http://www.mrrse.com/antibacterial-drugs-market

AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Allergen plc, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Pfizer, Inc. was observed to be the most promising and leading player in the Antibacterial drugs market. Major customers for their antibacterial drugs include hospitals, private clinics, physicians and patients.